These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17258887)

  • 1. Xenovaccinotherapy for colorectal cancer.
    Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
    Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenovaccinotherapy for melanoma.
    Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
    Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses.
    Seledtsova GV; Shishkov AA; Kaschenko EA; Seledtsov VI
    Biomed Pharmacother; 2016 Oct; 83():1247-1252. PubMed ID: 27565847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
    Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
    J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
    Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
    Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides.
    Miyagi Y; Imai N; Sasatomi T; Yamada A; Mine T; Katagiri K; Nakagawa M; Muto A; Okouchi S; Isomoto H; Shirouzu K; Yamana H; Itoh K
    Clin Cancer Res; 2001 Dec; 7(12):3950-62. PubMed ID: 11751487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
    Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
    Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
    Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
    Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer--a phase I clinical trial.
    Brill TH; Kübler HR; von Randenborgh H; Fend F; Pohla H; Breul J; Hartung R; Paul R; Schendel DJ; Gansbacher B
    J Gene Med; 2007 Jul; 9(7):547-60. PubMed ID: 17514769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.
    van der Burg SH; Menon AG; Redeker A; Bonnet MC; Drijfhout JW; Tollenaar RA; van de Velde CJ; Moingeon P; Kuppen PJ; Offringa R; Melief CJ
    Clin Cancer Res; 2002 May; 8(5):1019-27. PubMed ID: 12006514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
    Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
    Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
    Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
    Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell vaccination of patients with metastatic colorectal cancer.
    Burgdorf SK
    Dan Med Bull; 2010 Sep; 57(9):B4171. PubMed ID: 20816019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment of dendritoma vaccine and low-dose interleukin-2 in stage IV renal cell carcinoma patients induced clinical response: A pilot study.
    Wei YC; Sticca RP; Li J; Holmes LM; Burgin KE; Jakubchak S; Bouton-Verville H; Williamson J; Meyer K; Evans L; Martin J; Stephenson JJ; Trocha S; Smith S; Wagner TE
    Oncol Rep; 2007 Sep; 18(3):665-71. PubMed ID: 17671717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
    J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses in patients with metastatic renal cell carcinoma treated with dendritic cells pulsed with tumor lysate.
    Soleimani A; Berntsen A; Svane IM; Pedersen AE
    Scand J Immunol; 2009 Nov; 70(5):481-9. PubMed ID: 19874553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.